RDO patient pathway improves operative rates in cataracts

Article

Operative rates for cataract surgery are higher for the refined direct optometrist (RDO) patient pathway, compared to the GP pathway, reveals a recent investigation in the UK.

Operative rates for cataract surgery are higher for the refined direct optometrist (RDO) patient pathway, compared to the GP pathway, reveals a recent investigation in the UK.

A retrospective cohort study led by Dr Kevin Holmes, Bristol, and the Plymouth Royal Eye Infirmary, Plymouth, UK, was conducted on 4657 patients referred to the “One-stop cataract clinic” at Bristol Eye Hospital between 1 November 2008 and 31 May 2010.

Of the patients in the cohort, 4222 were referred via the traditional GP route and 435 were referred via the new refined direct optometrist (RDO) route. The team compared the operative rate, which was identified as the conversion to surgery from referral.

Operative rates were higher for the RDO pathway, compared to the GP pathway at 91.9% and 82.4%, respectively. Combining referral information from optometrists and GPs creates a high-quality and efficient cataract surgery patient pathway.

Combining referral information also had major economic advantages and could be adopted at a national level in the UK.

The abstract can be found in the latest issue of the Journal of Cataract and Refractive Surgery.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.